By Fineline Cube 
On March 19, 2025, Convalife Pharmaceuticals and XLement announced a strategic partnership to establish the “AI-Powered Innovative Drug Molecular Interaction Joint Laboratory.” This collaboration integrates expertise in AI algorithm development, high-throughput molecular interaction detection, and oncology and antiviral drug research, aiming to revolutionize drug discovery through the integration of MetaSPR sensor chip technology and machine learning.
Convalife Pharmaceuticals: Vision and Pipeline
Convalife Pharmaceuticals, a China-based innovative drug development company with a global vision, is led by a core team of top executives and scientists from leading pharmaceutical companies in the US and China. Focused on developing breakthrough therapies in oncology, virology, and anti-aging, the company’s pipeline includes several promising candidates: the second-generation PARP inhibitor CVL218, the bispecific antibody CVL006 in clinical trials, the PI3Kβ/δ dual inhibitor CVL237, and the pan-HER inhibitor CVL009.
XLement’s Technological Edge
XLement brings its internationally recognized technology platform in molecular interaction research, featuring high-throughput bio-molecular interaction analysis, microfluidic chips, and AI-assisted design. These technologies significantly enhance the efficiency of drug development, from target validation to candidate drug screening, positioning the collaboration at the forefront of innovation in pharmaceutical R&D.-Fineline Info & Tech